F.Hoffmann-La Roche (HLR) is part of the Swiss based multinational healthcare giant Roche, which manufactures leading cancer treatment drugs Avastin, Rituxan and Herceptin. Patent protection for these substances in Russia has expired, and generic company BIOCAD was successful in launching biosimilars of HLR’s originator medicines in the Russian market in years 2014-2016. Roughly at the same time, Roche sharply reduced the prices of its branded medicines imported in Russia, thus hindering BIOCAD’s market entry…
